Evidence for PTEN-independent Akt activation and Akt-independent p27Kip1 expression in advanced bladder cancer

Mundhenk,J.; Hennenlotter,J.; Zug,L.; Alloussi,S.h.; Todenhoefer,T.; Gakis,G.; Aufderklamm,S.; Scharpf,M.; Kuehs,U.; Stenzl,A.; Schwentner,C.

doi:10.3892/ol.2011.374

Evidence for PTEN-independent Akt activation and Akt-independent p27Kip1 expression in advanced bladder cancer

Authors:
- J. Mundhenk
- J. Hennenlotter
- L. Zug
- S.h. Alloussi
- T. Todenhoefer
- G. Gakis
- S. Aufderklamm
- M. Scharpf
- U. Kuehs
- A. Stenzl
- C. Schwentner
View Affiliations

Affiliations: Department of Urology, Eberhard-Karls University Tuebingen, D-72076 Tübingen, Germany, Department of Pathology, Eberhard-Karls University, Tuebingen, Germany
Published online on: August 5, 2011 https://doi.org/10.3892/ol.2011.374
Pages: 1089-1093

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the treatment of advanced bladder cancer (BC), attention has recently focused on small molecule therapy concerning EGFR and the downstream Akt signalling pathway. Cellular deregulation processes are poorly understood, and biological determinants for the selection of therapy and monitoring are currently not available. The proteins PTEN, p-Akt and p27Kip1 are suggested to be potentially significant biomarkers of Akt signalling. In this study, we investigated the expression of these proteins in advanced BC. PTEN, p-Akt and p27Kip1 expression was determined immunohistochemically in 86 T2-4 BC specimens using a tissue microarray technique. Staining was documented with regard to intensity, cellular frequency and a multiplied staining score. Staining characteristics of the three proteins were correlated by regression analysis with the parameters of tumour stage and grade. A positive correlation was observed in the expression scores of PTEN and p-Akt, p-Akt and p27Kip1 as well as PTEN and p27Kip1 (p<0.02 for all combinations). The positive correlation between PTEN and p-Akt resulted mainly due to the strong correlation of PTEN intensity with p-Akt (p=0.0003 and p=0.0006 to p-Akt frequency and intensity, respectively). A positive correlation between p-Akt and p27Kip1 was noted for p-Akt frequency as well as intensity (p<0.05 for all combinations). The positive correlation between PTEN and p27Kip1 resulted due to the correlation of PTEN intensity alone with p27Kip1 (p<0.03 for p27Kip1 frequency and intensity), whereas no significance was noted for PTEN frequency. No correlation was found between T or G and expression of the proteins. However, activation of Akt in BC is known to occur independently of PTEN protein loss and appears not to cause a decrease of p27Kip1. However, a direct regulatory impact of PTEN on p27Kip1 was found. PTEN intensity, rather than frequency, appears to be a superior biomarker. These results may provide information to support research into protein profiling-predicted targeted therapy for BC. Correlations to benign urothelium, superficial BC specimens and follow-up data remain to be investigated.

View Figures

View References

1	Parkin M, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 19:666–675. 2001.PubMed/NCBI
3	Netto G and Epstein J: Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology. 42:384–394. 2010. View Article : Google Scholar : PubMed/NCBI
4	Altomare D and Testa J: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI
5	Samuels Y and Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
6	Sherr C and Roberts J: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
7	Azim H, Azim H and Escudier B: Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol. 5:269–280. 2010. View Article : Google Scholar : PubMed/NCBI
8	Mass R, Press M, Anderson S, et al: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 6:240–246. 2005. View Article : Google Scholar : PubMed/NCBI
9	Graff JR, Konicek BW, McNulty AM, et al: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem. 275:24500–24505. 2000. View Article : Google Scholar : PubMed/NCBI
10	Merseburger A, Hennenlotter J, Kuehs U, et al: Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int. 80:372–377. 2008. View Article : Google Scholar : PubMed/NCBI
11	Hennenlotter J, Ohneseit P, Simon P, et al: PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas – implications for Akt activation. Oncol Rep. 19:1141–1147. 2008.
12	Kurose K, Zhou X-P, Araki T, Cannistra S, Maher E and Eng C: Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclinD1 expression, in primary epithelial ovarian carcinomas. Am J Pathol. 158:2097–2106. 2001. View Article : Google Scholar : PubMed/NCBI
13	Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 10:657–662. 2001. View Article : Google Scholar : PubMed/NCBI
14	Theodorescu D, Broder SR, Boyd JC, Mills SE and Frierson HF: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer. 80:2109–2119. 1997. View Article : Google Scholar : PubMed/NCBI
15	Blain S, Scher H, Cordon-Cardo C and Koff A: p27 as a target for cancer therapeutics. Cancer Cell. 3:111–115. 2003. View Article : Google Scholar
16	Chiarle R, Pagano M and Inghirami G: The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 3:91–94. 2001. View Article : Google Scholar : PubMed/NCBI
17	Seki R, Ohshima K, Fujisaki T, et al: Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Ann Oncol. 21:833–841. 2010. View Article : Google Scholar : PubMed/NCBI
18	Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JFR and Ellis IO: The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 204:93–100. 2004. View Article : Google Scholar : PubMed/NCBI
19	Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
20	Khaleghpour K, Li Y, Banville D, Yu Z and Shen SH: Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis. 25:241–248. 2004. View Article : Google Scholar : PubMed/NCBI
21	Shi W, Zhang X, Pintilie M, et al: Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer. 104:195–203. 2003. View Article : Google Scholar : PubMed/NCBI
22	Yoganathan TN, Costello P, Chen X, et al: Integrin-linked kinase (ILK): a ‘hot’ therapeutic target. Biochem Pharmacol. 60:1115–1119. 2000.
23	Persad S, Attwell S, Gray V, et al: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA. 97:3207–3212. 2000. View Article : Google Scholar : PubMed/NCBI
24	Widenmaier S, Sampaio A, Underhill M and McIntosh C: Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J Biol Chem. 284:10764–10773. 2009.PubMed/NCBI
25	Trotman L, Alimonti A, Scaglioni PP, Koutcher J, Cordon-Cardo C and Pandolfi PP: Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 441:523–527. 2006. View Article : Google Scholar : PubMed/NCBI
26	Blain S and Massagué J: Breast cancer banishes p27 from nucleus. Nat Med. 8:1076–1078. 2002. View Article : Google Scholar : PubMed/NCBI
27	Connor M, Kotchetkov R, Cariou S, et al: CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell. 14:201–213. 2003. View Article : Google Scholar : PubMed/NCBI
28	Liang J, Zubovitz J, Petrocelli T, et al: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 8:1153–1160. 2002. View Article : Google Scholar : PubMed/NCBI
29	Shin I, Yakes M, Rojo F, et al: PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med. 8:1145–1152. 2002. View Article : Google Scholar : PubMed/NCBI
30	Capodanno A, Camerini A, Orlandini C, et al: Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol. 40:1408–1417. 2009. View Article : Google Scholar : PubMed/NCBI
31	Pantuck A, Seligson D, Klatte T, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
32	Chen M, Gu J, Delclos G, et al: Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 31:1387–1391. 2010. View Article : Google Scholar : PubMed/NCBI
33	Shariat S, Ashfaq R, Sagalowsky A and Lotan Y: Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 177:481–487. 2007. View Article : Google Scholar : PubMed/NCBI
34	Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P and Vieillefond A: Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 21:815–819. 2010.PubMed/NCBI
35	Havaleshko D, Smith SC, Cho H, et al: Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia. 11:1185–1193. 2009.PubMed/NCBI
36	Miyake M, Ishii M, Koyama N, et al: 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther. 332:795–802. 2010.